<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Pharmacol Pharmacother</journal-id><journal-id journal-id-type="iso-abbrev">J Pharmacol Pharmacother</journal-id><journal-id journal-id-type="publisher-id">JPP</journal-id><journal-title-group><journal-title>Journal of Pharmacology &#x00026; Pharmacotherapeutics</journal-title></journal-title-group><issn pub-type="ppub">0976-500X</issn><issn pub-type="epub">0976-5018</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28163535</article-id><article-id pub-id-type="pmc">5242027</article-id><article-id pub-id-type="publisher-id">JPP-7-155</article-id><article-id pub-id-type="doi">10.4103/0976-500X.195897</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Lesinurad: A significant advancement or just another addition to existing therapies of gout?</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Gupta</surname><given-names>Ajay</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Sharma</surname><given-names>Pramod Kumar</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Misra</surname><given-names>Arup Kumar</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Singh</surname><given-names>Surjit</given-names></name><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff id="aff1"><italic>Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India</italic></aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Pramod Kumar Sharma, Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India. E-mail: <email xlink:href="pramod309@gmail.com">pramod309@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Oct-Dec</season><year>2016</year></pub-date><volume>7</volume><issue>4</issue><fpage>155</fpage><lpage>158</lpage><history><date date-type="received"><day>22</day><month>7</month><year>2016</year></date><date date-type="rev-recd"><day>27</day><month>9</month><year>2016</year></date><date date-type="accepted"><day>13</day><month>10</month><year>2016</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2016 Journal of Pharmacology and Pharmacotherapeutics</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.</license-p></license></permissions><abstract><p>Gout is a metabolic disorder that usually presents as recurrent episodes of acute arthritis due to deposition of crystals in joints and cartilages. Despite the availability of several drugs for gout, its management is still less than adequate. There is always a search for newer, safer, and more potent urate-lowering therapies for treating patients inadequately controlled with available drugs. Lesinurad in combination with a xanthine oxidase inhibitor provides an effective mode of therapy in the management of hyperuricemia associated with gout. Lesinurad is a selective uric acid transporter 1 (URAT1) inhibitor. URAT1 is responsible for the majority of uric acid absorption from kidneys to the circulation. Lesinurad was granted marketing approval based on three randomized, double-blind, placebo-controlled; phase III clinical trials. It is devoid of interaction with organic anion transporters (OATs) such as OAT1 and 3, responsible for drug-drug interactions, an undesirable property associated with probenecid. On-going research is more focused on reducing inflammation consequent to deposition of crystals rather than production and excretion of urate. Various targets are being explored, and interleukin-1 beta inhibition seems to be one of the most promising approaches.</p></abstract><kwd-group><title>Key words</title><kwd>Hyperuricemia</kwd><kwd>lesinurad</kwd><kwd>uric acid transporter 1</kwd><kwd>xanthine oxidase inhibitor</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>INTRODUCTION</title><p>Gout is a metabolic disorder wherein fundamental biochemical abnormality is hyperuricemia.[<xref rid="ref1" ref-type="bibr">1</xref>] It clinically presents as recurrent episodes of acute arthritis due to deposition of monosodium urate crystals in joints and cartilage.[<xref rid="ref2" ref-type="bibr">2</xref>] The crystallization of uric acid depends on several factors such as temperature, pH, concentration of cations, the level of articular dehydration, and the presence of such nucleating agents as nonaggregated proteoglycans, insoluble collagens, and chondroitin sulfate.[<xref rid="ref3" ref-type="bibr">3</xref>] In comparison to its hypoxanthine and xanthine precursors, uric acid is relatively insoluble. Low temperature favors crystal deposition making peripheral regions of the body more susceptible.[<xref rid="ref4" ref-type="bibr">4</xref>] Urate crystals through toll-like receptor pathway lead to activation of the NALP3 inflammasome with the release of proinflammatory cytokines including interleukin-1 beta (IL-1&#x003b2;) and tumor necrosis factor (TNF)-&#x003b1;. These cytokines, in turn, cause endothelial activation and attraction of neutrophils to the site of inflammation.[<xref rid="ref5" ref-type="bibr">5</xref><xref rid="ref6" ref-type="bibr">6</xref><xref rid="ref7" ref-type="bibr">7</xref>] Urate is the end product of purine metabolism. It is produced from xanthine and hypoxanthine by the action of the enzyme xanthine oxidase. Urate is excreted primarily through kidneys. Hyperuricemia can occur either due to overproduction or underexcretion by the kidneys, the latter being more common.</p><p>The recommended serum uric acid (SUA) target to durably improve the signs and symptoms of gout is &#x0003c;6 mg/dL.[<xref rid="ref8" ref-type="bibr">8</xref><xref rid="ref9" ref-type="bibr">9</xref><xref rid="ref10" ref-type="bibr">10</xref>] However, a target of SUA &#x0003c;5 mg/dL is recommended for greater disease severity, such as patients with tophaceous gout.[<xref rid="ref8" ref-type="bibr">8</xref><xref rid="ref9" ref-type="bibr">9</xref>]</p><p>Agents used to treat hyperuricemia can be grouped into three categories based on their mechanism of action: Drugs that decrease uric acid production (xanthine oxidase inhibitors [XOIs]; allopurinol and febuxostat); drugs that increase urinary uric acid excretion (probenecid); and drugs that enzymatically degrade excess circulating uric acid (pegloticase).</p><p>Newer targets for treating gout have been persistently explored because none of the currently used drugs can be called ideal. This is primarily because of ineffectiveness in achieving target SUA levels and adverse effects associated with available therapies. Considering under-excretion of uric acid as major cause of hyperuricemia, in recent years important urate transport proteins such as the human uric acid transporter 1 (URAT1) and the fructose transporter SLC2A9 have been characterized.[<xref rid="ref11" ref-type="bibr">11</xref><xref rid="ref12" ref-type="bibr">12</xref>] Lesinurad, a newer drug to treat chronic refractory gout by targeting the URAT1 transporter, has been approved recently by the US Food and Drug Administration in combination with an XOI.[<xref rid="ref13" ref-type="bibr">13</xref>] It has also been currently approved by the European Commission for marketing authorization throughout the European Union in February 2016.[<xref rid="ref14" ref-type="bibr">14</xref>]</p></sec><sec id="sec1-2"><title>PHARMACOLOGICAL BASIS FOR USE OF LESINURAD IN PATIENTS OF GOUT</title><p>Urate homeostasis depends on the balance between production, complex processes of secretion and reabsorption in the kidney tubule as well as excretion in the intestine. It is estimated that approximately 30% of urate excretion is by the intestine and 70% by renal mechanisms.[<xref rid="ref15" ref-type="bibr">15</xref>] URAT1 is a 12-transmembrane domain containing protein found in the apical membrane of proximal tubular epithelial cells and transports urate in exchange for Cl &#x02013; or organic anions. The antiuricosuric agents lactate, pyrazinoate, and nicotinate can serve as a substrate for the antiporter activity of URAT1 to increase urate reabsorption. On the other hand, URAT1 is inhibited by the classical uricosuric agents benzbromarone, probenecid, and losartan.[<xref rid="ref16" ref-type="bibr">16</xref><xref rid="ref17" ref-type="bibr">17</xref><xref rid="ref18" ref-type="bibr">18</xref>] Uric acid is freely filtered in the kidney at the glomerulus and enters the proximal tubule where more than 90% is reabsorbed back into the bloodstream through URAT1.[<xref rid="ref19" ref-type="bibr">19</xref>]</p><p>Any uric acid that is not reabsorbed moves to the distal part of the nephron and is excreted in the urine. In the majority of patients with gout, hyperuricemia is caused by inefficient renal excretion of uric acid.[<xref rid="ref20" ref-type="bibr">20</xref>] Lesinurad is a selective uric acid reabsorption inhibitor that inhibits the URAT1; thus, increases uric acid excretion. Lesinurad also inhibits organic anion transporter 4 (OAT4), an URAT1 involved in diuretic-induced hyperuricemia.[<xref rid="ref21" ref-type="bibr">21</xref>]</p><p>XOIs such as allopurinol and febuxostat act by reducing the production of uric acid, primarily in the liver and intestine. Targeting both excretion and production of uric acid provide a dual mechanism approach to effectively lower SUA levels. This combination approach is considered ideal for those who do not achieve SUA targets on a XOI alone, and in patients with uncontrolled gout as evident by continuing disease activity.[<xref rid="ref8" ref-type="bibr">8</xref><xref rid="ref9" ref-type="bibr">9</xref>]</p><p>Lesinurad has rapid oral absorption and is highly plasma protein bound. Approximately, half of the oral dose is cleared via CYP2C9 metabolisms;[<xref rid="ref22" ref-type="bibr">22</xref>] therefore, caution is required when it is administered with moderate CYP2C9 inhibitors (e.g., fluconazole, amiodarone). Lesinurad has no relevant effect on anionic or cationic transporters such as OAT1 and OAT3 which are mainly responsible for drug-drug interactions associated with probenecid.[<xref rid="ref22" ref-type="bibr">22</xref>]</p></sec><sec id="sec1-3"><title>CLINICAL TRIALS</title><p>The regulatory approval of lesinurad is based on three randomized, double-blind, placebo-controlled; phase III clinical trials &#x02013; CLEAR 1, CLEAR 2, and CRYSTAL.</p><p>Two replicate studies (CLEAR 1, CLEAR 2) evaluated lesinurad (200 or 400 mg oral, once daily) in combination with allopurinol versus allopurinol + placebo in subjects with gout aged 18&#x02013;85 years. Subjects were required to be on stable allopurinol doses &#x02265;300 mg (&#x02265;200 mg for moderate renal impairment), have SUA &#x02265;6.5 mg/dL at screening, and history of &#x02265;2 gout flares in the prior 12 months. The primary endpoint was the proportion of subjects meeting SUA target of &#x0003c;6.0 mg/dL by 6 months. Lesinurad (200 or 400 mg) in combination with allopurinol achieved SUA target at 6 months by ~2&#x02013;2.5-fold compared to allopurinol alone.[<xref rid="ref23" ref-type="bibr">23</xref>]</p><p>Similarly, the CRYSTAL[<xref rid="ref24" ref-type="bibr">24</xref>] study evaluated lesinurad in combination with febuxostat against febuxostat monotherapy in patients with tophaceous gout. Not only the combination therapy resulted in the higher proportion of patients achieving SUA &#x0003c;5 mg/dL at 6 months but also achieved greater tophus area resolution.</p></sec><sec id="sec1-4"><title>DOES LESINURAD HAS AN EDGE OVER EXISTING URICOSURICS?</title><p>
<list list-type="bullet"><list-item><p>OAT1 and OAT3 are organic transporters involved in the movement of uric acid through the basolateral membrane to the circulation. Many drugs such as tenofovir and emtricitabine, reverse transcriptase inhibitors depend on OAT1 and OAT3 for clearance through kidneys. Existing urate lowering drugs such as probenecid and benzbromarone inhibit OAT1 and OAT3 thus posing a significant problem of drug&#x02013;drug interactions. Lesinurad devoid of interaction with OAT1 or OAT3, is a major breakthrough in solving this hurdle of clinically relevant drug&#x02013;drug interactions[<xref rid="ref25" ref-type="bibr">25</xref>]</p></list-item><list-item><p>It has been shown in animal[<xref rid="ref26" ref-type="bibr">26</xref>] as well as clinical[<xref rid="ref27" ref-type="bibr">27</xref>] studies that no unfavorable pharmacokinetic interaction or interference with urinary excretion exists between lesinurad and XOIs such as allopurinol or oxypurinol and febuxostat. Coadministration of lesinurad and XOIs thus could safely be used to accelerate urate reduction in gout patients</p></list-item><list-item><p>Continued use of allopurinol at suboptimal doses in patients with renal insufficiency could worsen renal failure, or sometimes may precipitate fatal hypersensitivity syndrome.[<xref rid="ref28" ref-type="bibr">28</xref>] Under-dosing for fear of side-effects is clearly a hindrance in achieving therapeutic goal. Combining lesinurad at a fixed dose of 200 mg/day with XOIs helps in controlling hyperuricemia more effectively. Evidence is available that effective treatment of hyperuricemia may improve renal functions. Introduction of lesinurad has effectively addressed the issue of allopurinol under dosing</p></list-item><list-item><p>It also inhibits OAT4, a URAT1 involved in diuretic-induced hyperuricemia. In future, it might be indicated to prevent hyperuricemia usually associated with prolonged diuretic (loop or thiazides) therapy.</p></list-item></list>
</p></sec><sec id="sec1-5"><title>THERAPIES IN PIPELINE</title><p>Further research for the management of gout is directed towards limiting the inflammatory events that are initiated by the deposition of urate crystals. Various specific targets in the inflammatory pathway of gout are:</p><p>
<list list-type="bullet"><list-item><p>NALP3 inflammasome and IL-1&#x003b2;[<xref rid="ref5" ref-type="bibr">5</xref><xref rid="ref6" ref-type="bibr">6</xref><xref rid="ref7" ref-type="bibr">7</xref>]</p></list-item><list-item><p>Complement C5b-9 membrane attack complex,[<xref rid="ref29" ref-type="bibr">29</xref>] agonism of phagocyte melanocortin receptor 3 (shown to be a direct peripheral target of adrenocorticotropic hormone), the chemokines CXC1 and CXCL8, TNF-&#x003b1;.[<xref rid="ref30" ref-type="bibr">30</xref>]</p></list-item></list> Among above targets, IL-1&#x003b2; neutralization appears to play a central role in the control of inflammatory events. Both animal[<xref rid="ref31" ref-type="bibr">31</xref>] and clinical[<xref rid="ref32" ref-type="bibr">32</xref>] studies have demonstrated the effect of IL-1&#x003b2; inhibition by anakinra in gout. Based on the above findings, biologics against IL-1&#x003b2; such as canakinumab and rilonacept were evaluated for its effect in patients of acute gout or those who were intolerant to existing therapies. Both the agents demonstrated a significant improvement in the patients' symptoms such as gout flares, and pain as compared to placebo or corticosteroids.[<xref rid="ref25" ref-type="bibr">25</xref>] Further clinical trials on a large scale with IL-1&#x003b2; inhibitors will help in establishing their role in patients of gout.</p></sec><sec sec-type="conclusions" id="sec1-6"><title>CONCLUSION</title><p>Apprehensions and confusions about how to use existing drugs in the management of gout is a perpetual issue, and merely addition of new drugs is not sufficient to resolve these misconceptions. Availability of a new therapy always offers an opportunity for us to revisit the treatment strategies to improve outcome in this highly treatable disease. Concerns clearly warrant additional treatment options for patients with gout who are unable to achieve and sustain recommended SUA levels with currently available therapies. Lesinurad inhibits URAT1, increases uric acid excretion and thereby lowers SUA. Lesinurad, when used in combination with an XOIs (allopurinol or febuxostat), targets both aspects of SUA regulation (production and excretion) providing a dual mechanism approach to more effectively lower SUA.</p><sec id="sec2-1"><title>Financial support and sponsorship</title><p>Nil.</p></sec><sec id="sec2-2" sec-type="COI-statement"><title>Conflicts of interest</title><p>There are no conflicts of interest.</p></sec></sec></body><back><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tausche</surname><given-names>AK</given-names></name><name><surname>Jansen</surname><given-names>TL</given-names></name><name><surname>Schr&#x000f6;der</surname><given-names>HE</given-names></name><name><surname>Bornstein</surname><given-names>SR</given-names></name><name><surname>Aringer</surname><given-names>M</given-names></name><name><surname>M&#x000fc;ller-Ladner</surname><given-names>U</given-names></name></person-group><article-title>Gout &#x02013; current diagnosis and treatment</article-title><source>Dtsch Arztebl Int</source><year>2009</year><volume>106</volume><fpage>549</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">19795010</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Borazan</surname><given-names>NH</given-names></name><name><surname>Furst</surname><given-names>DE</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Katzung</surname><given-names>BG</given-names></name><name><surname>Trevor</surname><given-names>AJ</given-names></name></person-group><article-title>Nonsteroidal Anti-inflammatory drugs, disease modifying antirheumatic drugs, nonopioid analgesics, &#x00026; drugs used in gout</article-title><source>Basic and Clinical Pharmacology</source><year>2015</year><edition>13th ed</edition><publisher-loc>New Delhi</publisher-loc><publisher-name>Mcgraw-Hill Education (India) Private Limited</publisher-name><fpage>634</fpage></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>HK</given-names></name><name><surname>Mount</surname><given-names>DB</given-names></name><name><surname>Reginato</surname><given-names>AM</given-names></name></person-group><article-title>American College of Physicians; American Physiological Society. Pathogenesis of gout</article-title><source>Ann Intern Med</source><year>2005</year><volume>143</volume><fpage>499</fpage><lpage>516</lpage><pub-id pub-id-type="pmid">16204163</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>MD</given-names></name><name><surname>Siegel</surname><given-names>LB</given-names></name><name><surname>Alloway</surname><given-names>JA</given-names></name></person-group><article-title>Gout and hyperuricemia</article-title><source>Am Fam Physician</source><year>1999</year><volume>59</volume><fpage>925</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">10068714</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinon</surname><given-names>F</given-names></name><name><surname>P&#x000e9;trilli</surname><given-names>V</given-names></name><name><surname>Mayor</surname><given-names>A</given-names></name><name><surname>Tardivel</surname><given-names>A</given-names></name><name><surname>Tschopp</surname><given-names>J</given-names></name></person-group><article-title>Gout-associated uric acid crystals activate the NALP3 inflammasome</article-title><source>Nature</source><year>2006</year><volume>440</volume><fpage>237</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">16407889</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>P&#x000e9;trilli</surname><given-names>V</given-names></name><name><surname>Dostert</surname><given-names>C</given-names></name><name><surname>Muruve</surname><given-names>DA</given-names></name><name><surname>Tschopp</surname><given-names>J</given-names></name></person-group><article-title>The inflammasome: A danger sensing complex triggering innate immunity</article-title><source>Curr Opin Immunol</source><year>2007</year><volume>19</volume><fpage>615</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">17977705</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dalbeth</surname><given-names>N</given-names></name><name><surname>Haskard</surname><given-names>DO</given-names></name></person-group><article-title>Inflammation and tissue damage in crystal deposition diseases</article-title><source>Curr Opin Rheumatol</source><year>2005</year><volume>17</volume><fpage>314</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">15838243</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richette</surname><given-names>P</given-names></name><name><surname>Doherty</surname><given-names>M</given-names></name><name><surname>Pascual</surname><given-names>E</given-names></name><name><surname>Barskova</surname><given-names>V</given-names></name><name><surname>Becce</surname><given-names>F</given-names></name><name><surname>Coyfish</surname><given-names>M</given-names></name><etal/></person-group><article-title>SAT0531 updated eular evidence-based recommendations for the management of gout</article-title><source>Annals of the Rheumatic Diseases</source><year>2014</year><month>6</month><day>1</day><volume>73</volume><issue>Suppl 2</issue><fpage>783</fpage></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khanna</surname><given-names>D</given-names></name><name><surname>Fitzgerald</surname><given-names>JD</given-names></name><name><surname>Khanna</surname><given-names>PP</given-names></name><name><surname>Bae</surname><given-names>S</given-names></name><name><surname>Singh</surname><given-names>MK</given-names></name><name><surname>Neogi</surname><given-names>T</given-names></name><etal/></person-group><article-title>American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia</article-title><source>Arthritis Care Res (Hoboken)</source><year>2012</year><volume>64</volume><fpage>1431</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">23024028</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jordan</surname><given-names>KM</given-names></name><name><surname>Cameron</surname><given-names>JS</given-names></name><name><surname>Snaith</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Doherty</surname><given-names>M</given-names></name><name><surname>Seckl</surname><given-names>J</given-names></name><etal/></person-group><article-title>British Society for rheumatology and British Health Professionals in rheumatology guideline for the management of gout</article-title><source>Rheumatology (Oxford)</source><year>2007</year><volume>46</volume><fpage>1372</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">17522099</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Unger</surname><given-names>S</given-names></name><name><surname>Tausche</surname><given-names>AK</given-names></name><name><surname>Kopprasch</surname><given-names>S</given-names></name><name><surname>Bornstein</surname><given-names>SR</given-names></name><name><surname>Aringer</surname><given-names>M</given-names></name><name><surname>Gr&#x000e4;ssler</surname><given-names>J</given-names></name></person-group><article-title>Molecular basis of primary renal hyperuricemia: Role of the human urate transporter hURAT1</article-title><source>Z Rheumatol</source><year>2007</year><volume>66</volume><fpage>556, 58</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">17891408</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graessler</surname><given-names>J</given-names></name><name><surname>Graessler</surname><given-names>A</given-names></name><name><surname>Unger</surname><given-names>S</given-names></name><name><surname>Kopprasch</surname><given-names>S</given-names></name><name><surname>Tausche</surname><given-names>AK</given-names></name><name><surname>Kuhlisch</surname><given-names>E</given-names></name><etal/></person-group><article-title>Association of the human urate transporter 1 with reduced renal uric acid excretion and hyperuricemia in a German Caucasian population</article-title><source>Arthritis Rheum</source><year>2006</year><volume>54</volume><fpage>292</fpage><lpage>300</lpage><pub-id pub-id-type="pmid">16385546</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="webpage"><source>ZURAMPIC (Lesinurad) Approved by US FDA for Patients with Gout</source><year>2015</year><month>12</month><day>22</day><date-in-citation>Last cited on 2016 Jun 16</date-in-citation><comment>Available from: <uri xlink:type="simple" xlink:href="https://www.astrazeneca.com/mediacentre/press-releases/2015/ZURAMPIC-lesinurad-approved-by-USFDA-for-patients-with-gout-22122015.html">https://www.astrazeneca.com/mediacentre/press-releases/2015/ZURAMPIC-lesinurad-approved-by-USFDA-for-patients-with-gout-22122015.html</uri></comment></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="book"><collab>ZURAMPIC</collab><source>EPAR Summary for the Public</source><year>2016</year><date-in-citation>Last cited on 2016 Jun 16</date-in-citation><publisher-loc>London</publisher-loc><publisher-name>European Medical Agency</publisher-name><comment>Available from: <uri xlink:type="simple" xlink:href="http://www.ema.europa.eu/docs/en_GB/document_library/EPAR-Summary_for_the_public/human/003932/WC500203068.pdf">http://www.ema.europa.eu/docs/en_GB/document_library/EPAR-Summary_for_the_public/human/003932/WC500203068.pdf</uri></comment></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pascual</surname><given-names>E</given-names></name><name><surname>Perdiguero</surname><given-names>M</given-names></name></person-group><article-title>Gout, diuretics and the kidney</article-title><source>Ann Rheum Dis</source><year>2006</year><volume>65</volume><fpage>981</fpage><lpage>2</lpage><pub-id pub-id-type="pmid">16837492</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Enomoto</surname><given-names>A</given-names></name><name><surname>Kimura</surname><given-names>H</given-names></name><name><surname>Chairoungdua</surname><given-names>A</given-names></name><name><surname>Shigeta</surname><given-names>Y</given-names></name><name><surname>Jutabha</surname><given-names>P</given-names></name><name><surname>Cha</surname><given-names>SH</given-names></name><etal/></person-group><article-title>Molecular identification of a renal urate anion exchanger that regulates blood urate levels</article-title><source>Nature</source><year>2002</year><volume>417</volume><fpage>447</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">12024214</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Tsuchida</surname><given-names>S</given-names></name><name><surname>Oyamada</surname><given-names>T</given-names></name><name><surname>Ohno</surname><given-names>T</given-names></name><name><surname>Miyashita</surname><given-names>M</given-names></name><name><surname>Saito</surname><given-names>S</given-names></name><etal/></person-group><article-title>Recurrent URAT1 gene mutations and prevalence of renal hypouricemia in Japanese</article-title><source>Pediatr Nephrol</source><year>2005</year><volume>20</volume><fpage>576</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">15772829</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ichida</surname><given-names>K</given-names></name><name><surname>Hosoyamada</surname><given-names>M</given-names></name><name><surname>Kamatani</surname><given-names>N</given-names></name><name><surname>Kamitsuji</surname><given-names>S</given-names></name><name><surname>Hisatome</surname><given-names>I</given-names></name><name><surname>Shibasaki</surname><given-names>T</given-names></name><etal/></person-group><article-title>Age and origin of the G774A mutation in SLC22A12 causing renal hypouricemia in Japanese</article-title><source>Clin Genet</source><year>2008</year><volume>74</volume><fpage>243</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">18492088</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reginato</surname><given-names>AM</given-names></name><name><surname>Mount</surname><given-names>DB</given-names></name><name><surname>Yang</surname><given-names>I</given-names></name><name><surname>Choi</surname><given-names>HK</given-names></name></person-group><article-title>The genetics of hyperuricaemia and gout</article-title><source>Nat Rev Rheumatol</source><year>2012</year><volume>8</volume><fpage>610</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">22945592</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>V&#x000e1;zquez-Mellado</surname><given-names>J</given-names></name><name><surname>Jim&#x000e9;nez-Vaca</surname><given-names>AL</given-names></name><name><surname>Cuevas-Covarrubias</surname><given-names>S</given-names></name><name><surname>Alvarado-Romano</surname><given-names>V</given-names></name><name><surname>Pozo-Molina</surname><given-names>G</given-names></name><name><surname>Burgos-Vargas</surname><given-names>R</given-names></name></person-group><article-title>Molecular analysis of the SLC22A12 (URAT1) gene in patients with primary gout</article-title><source>Rheumatology (Oxford)</source><year>2007</year><volume>46</volume><fpage>215</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16837472</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Handler</surname><given-names>J</given-names></name></person-group><article-title>Managing hypertensive patients with gout who take thiazide</article-title><source>J Clin Hypertens (Greenwich)</source><year>2010</year><volume>12</volume><fpage>731</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">20883235</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="webpage"><article-title>Lesinurad in Combination With a Xanthine Oxidase Inhibitor for Treatment of Hyperuricemia Associated With Gout</article-title><source>Ardea Biosciences</source><year>2015</year><date-in-citation>Last cited on 2016 Jun 15</date-in-citation><comment>Available from: <uri xlink:type="simple" xlink:href="http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM467951.pdf">http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM467951.pdf</uri></comment></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saag</surname><given-names>KG</given-names></name><name><surname>Adler</surname><given-names>S</given-names></name><name><surname>Bhakta</surname><given-names>N</given-names></name><name><surname>Fung</surname><given-names>M</given-names></name><name><surname>Kopicko</surname><given-names>J</given-names></name><name><surname>Storgard</surname><given-names>C</given-names></name><etal/></person-group><article-title>Lesinurad, a novel selective uric acid reabsorption inhibitor, in two phase III clinical trials: Combination Study of Lesinurad in Allopurinol Standard of Care Inadequate Responders (CLEAR 1 and 2)</article-title><source>Arthritis Rheum</source><year>2014</year><volume>66</volume><fpage>3533</fpage><lpage>4</lpage></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dalbeth</surname><given-names>N</given-names></name><name><surname>Jones</surname><given-names>G</given-names></name><name><surname>Terkeltaub</surname><given-names>R</given-names></name><name><surname>Khanna</surname><given-names>D</given-names></name><name><surname>Kopicko</surname><given-names>J</given-names></name><name><surname>Bhakta</surname><given-names>N</given-names></name><etal/></person-group><article-title>SAT0329 Lesinurad, a novel selective uric acid reabsorption inhibitor, in combination with febuxostat, in patients with tophaceous gout: The crystal phase III clinical trial</article-title><source>Ann Rheum Dis</source><year>2015</year><volume>74</volume><issue>Suppl 2</issue><fpage>778</fpage><pub-id pub-id-type="pmid">24395554</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burns</surname><given-names>CM</given-names></name><name><surname>Wortmann</surname><given-names>RL</given-names></name></person-group><article-title>Gout therapeutics: New drugs for an old disease</article-title><source>Lancet</source><year>2011</year><volume>377</volume><fpage>165</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">20719377</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Dick</surname><given-names>R</given-names></name><name><surname>Borges</surname><given-names>V</given-names></name><name><surname>Yazdani</surname><given-names>N</given-names></name><name><surname>Green</surname><given-names>A</given-names></name><name><surname>Manhard</surname><given-names>K</given-names></name><etal/></person-group><article-title>Evaluation of drug-drug interaction potential between RDEA594, allopurinol and febuxostat in preclinical species</article-title><source>Arthritis Rheum</source><year>2009</year><volume>60</volume><fpage>S412</fpage><lpage>3</lpage></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeh</surname><given-names>LT</given-names></name><name><surname>Shen</surname><given-names>Z</given-names></name><name><surname>Kerr</surname><given-names>B</given-names></name><name><surname>Tamai</surname><given-names>I</given-names></name><name><surname>Hingorani</surname><given-names>V</given-names></name><name><surname>Ong</surname><given-names>V</given-names></name><etal/></person-group><article-title>RDEA594, a potent URAT1 inhibitor without affecting other important renal transporters OAT1 and OAT3</article-title><source>Ann Rheum Dis</source><year>2009</year><volume>68</volume><issue>Suppl 3</issue><fpage>320</fpage></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hande</surname><given-names>KR</given-names></name><name><surname>Noone</surname><given-names>RM</given-names></name><name><surname>Stone</surname><given-names>WJ</given-names></name></person-group><article-title>Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency</article-title><source>Am J Med</source><year>1984</year><volume>76</volume><fpage>47</fpage><lpage>56</lpage></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tramontini</surname><given-names>N</given-names></name><name><surname>Huber</surname><given-names>C</given-names></name><name><surname>Liu-Bryan</surname><given-names>R</given-names></name><name><surname>Terkeltaub</surname><given-names>RA</given-names></name><name><surname>Kilgore</surname><given-names>KS</given-names></name></person-group><article-title>Central role of complement membrane attack complex in monosodium urate crystal-induced neutrophilic rabbit knee synovitis</article-title><source>Arthritis Rheum</source><year>2004</year><volume>50</volume><fpage>2633</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15334478</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cronstein</surname><given-names>BN</given-names></name><name><surname>Terkeltaub</surname><given-names>R</given-names></name></person-group><article-title>The inflammatory process of gout and its treatment</article-title><source>Arthritis Res Ther</source><year>2006</year><volume>8</volume><issue>Suppl 1</issue><fpage>S3</fpage></element-citation></ref><ref id="ref31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>So</surname><given-names>A</given-names></name><name><surname>De Smedt</surname><given-names>T</given-names></name><name><surname>Revaz</surname><given-names>S</given-names></name><name><surname>Tschopp</surname><given-names>J</given-names></name></person-group><article-title>A pilot study of IL-1 inhibition by anakinra in acute gout</article-title><source>Arthritis Res Ther</source><year>2007</year><volume>9</volume><fpage>R28</fpage><pub-id pub-id-type="pmid">17352828</pub-id></element-citation></ref><ref id="ref32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terkeltaub</surname><given-names>R</given-names></name><name><surname>Sundy</surname><given-names>JS</given-names></name><name><surname>Schumacher</surname><given-names>HR</given-names></name><name><surname>Murphy</surname><given-names>F</given-names></name><name><surname>Bookbinder</surname><given-names>S</given-names></name><name><surname>Biedermann</surname><given-names>S</given-names></name><etal/></person-group><article-title>The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: Results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study</article-title><source>Ann Rheum Dis</source><year>2009</year><volume>68</volume><fpage>1613</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">19635719</pub-id></element-citation></ref></ref-list></back></article>